Notable weight losses were achieved in both non-CKD and CKD patients
Immunologic Tolerance and Autoimmunity in Cellular and Molecular Immunology 2 AbbasA
The FDA has not approved any SGLT2 inhibitor or GLP-1 receptor agonist for type 1 diabetes, but their use in this patient population may continue due to the significant weight management and cardiorenal benefits observed in people with and without type 2 diabetes. In their study, the researchers noted that the differences in characteristics for patients prescribed these drug suggest their use was intended to address additional medical needs. From 2010 to 2023, the percentage of type 1 diabetes patients prescribed an agent from one of these two classes increased from 0.7% to 8.3%, with the bulk of the increase driven by GLP-1 agonists, reported Hui Shao, MD, PhD, of Emory University Rollins School of Public Health in Atlanta, and colleagues
Its Versatile Works for any peptide, any vial size, and any syringe type
Pharmacokinetics The pharmacokinetics of corticosteroids differ depending on the drug type and route of administration
Borchert A, Kalms J, Roth SR, Rademacher M, Schmidt A, Holzhutter H-G et al (2018) Crystal structure and functional characterization of selenocysteine-containing glutathione peroxidase 4 suggests an alternative mechanism of peroxide reduction
